Read the CEO Letter; 2016 Integrated Report 3.6 MB. . 2020 was a year none of us will ever forget. The 2020 Integrated Report continues the new digital and fully interactive format created in 2018. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it was selected as one of winners of the . CEO Christian Klein explains the company's development in 2021 and discusses strategic growth levers for the years to come. Eisai came to America in 1987 with one goal in mind: Create innovative new medicines to help patients, their families and caregivers. WOODCLIFF LAKE, N.J., Aug. 11, 2020 /PRNewswire/ -- Eisai Inc., an oncology- and neurology-focused pharmaceutical company and the U.S. subsidiary of Eisai Co., Ltd., . Analyst & Investor Briefing on 18.11.2022. Copyright Eisai Co., Ltd. All Rights Reserved. As shown in Figure 2, at a 95% confidence rate (p < 0.05 . Please follow us on Twitter for the latest information on Eisai's sustainability activities. By using this site, you agree to our use of cookies. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative . 2019. Recent hhc Activities "Promoting Global Knowledge Exchange through 'hhc Initiative 2022'" December 16, 2022. Nearly 20 kinds of Eisai's ESG investments have a delayed impact that affects long-term corporate value with statistical significance over a period of 5 to 10 years. By using this site, you agree to our use of cookies. Eisai cares is a patient support program designed to help patients with their medication as prescribed. Eisai Mexico has submitted for regulatory review several drug products to COFEPRIS (Federal Commission for the Protection against Sanitary Risks), while further developing its commercial operation for the introduction . adding the facilities should be integrated with hospitals and a healthcare staffing strategy prepared. Eisai contributes to the sustainability of society through ESG (Environmental, Social, Governance) initiatives. Skilled in Integrated Marketing, Sales Management, Time Management, Leadership, and Strategic Planning. Data Book FY2017 [From April 1, 2017 . Welcome to Eisai, India. Post Author: Post published: 21st May 2022 Post Category: junior architectural designer salary Post Comments: coachella festival demographics coachella festival demographics Our employees make, sell and distribute the world's most loved drinks brands, serving a consumer population . Letter from the CEO. [Select all that apply], With respect to your companys actions to advance the Sustainable Development Goals (SDGs), the COP describes: [Select all that apply]. Published. Through knowledge exchange, collaboration, and engagement, HKLSS aims to attract, cultivate, and retain talent in Hong Kong's life sciences and biotechnology sectors. The Texas Integrated Report describes the status of the state's waters, as required by Sections 305(b) and 303(d) of the federal Clean Water Act. Diversity of governance bodies and employees. Initiatives for Elimination of Neglected Tropical Diseases, Initiatives for Improving Access toMedicines for Non-communicable Diseases, Research & Development for Improving Access to Medicines, Initiatives for the Formation of a Carbon-free Society, Relationship with Industry Associations and Patient Groups (Advocacy), Relationship with People throughout Society. This website uses cookies to enhance your browsing experience. EISAI COMPLETES CONSTRUCTION OF THE 5TH MANUFACTURING BUILDING AT KAWASHIMA INDUSTRIAL PARK IN JAPANTO STRENGTHEN ITS IN-HOUSE PRODUCTION FUNCTION FOR FORMULATING ANTI-CANCER AGENT LENVIMA, LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-Free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced Endometrial Cancer Following Prior Systemic Therapy in Phase 3 StudyFirst Overall Survival Analysis for LENVIMA Plus KEYTRUDA Combination in a Phase 3 Study in Advanced Endometrial Cancer, BIOGEN FILES NEW DRUG APPLICATION FOR ADUCANUMAB IN JAPANIf approved, aducanumab would become the first treatment to meaningfully change the course of Alzheimers diseaseAducanumab is now under regulatory review in Japan, Europe and the United States, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT 43RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM, EISAI AND WREN THERAPEUTICS ENTER INTO RESEARCH COLLABORATION AGREEMENT FOR DRUG DISCOVERY FOR SYNUCLEINOPATHIESThis collaboration aims to develop a disease modifying treatment for synucleinopathies based on network kinetics of-synuclein misfolding and aggregation, EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT THE 74TH AMERICAN EPILEPSY SOCIETY ANNUAL MEETING, AbbVie and Eisai Announce an approval for additional indication of HUMIRA, a fully Human Anti-TNF Monoclonal Antibody, for the treatment of pyoderma gangrenosum for the first time in the world, EISAI COMMENCES PaDiCo SMARTPHONE APPLICATION SERVICE IN JAPAN TO SUPPORT THE DAILY LIVES OF PATIENTS WITH PARKINSONS DISEASEWITH SIMPLE OPERATION, APP RECORDS AND VISUALIZES SYMPTOMS TO SUPPORT COMMUNICATION BETWEEN PATIENTS AND DOCTORS, EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY ASIA PACIFIC INDEX 2020 FOR SEVENTH TIME, JYSELECA (FILGOTINIB) FOR RHEUMATOID ARTHRITIS LAUNCHES IN JAPANA once-daily, oral, JAK inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate response to conventional therapies, EISAI RECEIVES APPROVAL FOR INDICATION EXPANSION OF ANTI-EPILEPTIC AGENT FYCOMPA FOR USE IN PEDIATRIC PATIENTS, LENVIMA Plus KEYTRUDA Demonstrated Statistically Significant Improvement in Progression-Free Survival, Overall Survival and Objective Response Rate Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaLENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus SunitinibResults of Investigational Phase 3 CLEAR Trial (Study 307)/KEYNOTE-581 to be Presented at Upcoming Medical Meeting, Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimers Disease Using BloodThe Content Presented at the 13th Clinical Trials on Alzheimers Disease (CTAD) Conference, Update on FDA Advisory Committees meeting on aducanumab in Alzheimers disease, European Medicines Agency Accepts Biogens Aducanumab Marketing Authorization Application for Alzheimer's DiseaseIf approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimers disease and to meaningfully change the course of Alzheimers disease, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE 13TH CLINICAL TRIALS ON ALZHEIMERS DISEASE CONFERENCE, EISAI AND JD HEALTH ESTABLISH A JOINT VENTURE COMPANY IN CHINA TO IMPLEMENT HEALTH SERVICE PLATFORMAiming to make a new contribution through a One-Stop Online Service for people living with Dementia in China, GLOBAL COALITION FOR ADAPTIVE RESEARCH, AMGEN, AND EISAI ANNOUNCE FIRST PATIENT ENROLLED IN INTERNATIONAL COVID-19 TRIALAMGEN AND EISAI TO PARTICIPATE IN THE IMMUNE MODULATION DOMAIN OF REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS HOSPITALIZED WITH COVID-19AMGENS APREMILAST AND EISAIS ERITORAN TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES WITHIN THE REMAP NETWORK, Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies, NOTICE REGARDING BIOGENS DISCLOSURE ABOUT THE SUBMISSION OF MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR ADUCANUMAB FOR ALZHEIMERS DISEASE, SUPPLEMENTARY NEW DRUG APPLICATIONS FOR ANTI-EPILEPTIC DRUG FYCOMPA AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES ACCEPTED IN CHINA, THE UNIVERSITY OF TOKYO AND EISAI ANNOUNCE RESEARCH COLLABORATION FOR THE DEVELOPMENT AND DRUG DISCOVERY OF TARGETED PROTEIN DEGRADATION TECHNOLOGYEstablishment of Social Cooperation Program Protein Degradation Drug Discovery, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR COVID-19 UTILIZING ERITORAN AND E6011 CONCLUDED, NON-CLINICAL RESEARCH ACTIVITIES COMMENCEAdopted for the public call for AMED "Development of therapeutic drugs for the novel coronavirus infection (COVID-19)", Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea, JYSELECA (FILGOTINIB) APPROVED IN JAPAN FOR RHEUMATOID ARTHRITISFilgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials, EISAI RECEIVES POSITIVE OPINION FROM EMAS CHMP ON USE OF ANTIEPILEPTIC AGENT FYCOMPA IN PEDIATRIC PATIENTS, Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy, EISAI PRESENTS LATEST DATA OF PHASE I CLINICAL TRIAL ON LIPOSOMAL FORMULATION OF ANTI-CANCER AGENT HALAVEN (ERIBULIN) AT ESMO VIRTUAL CONGRESS 2020, EISAI ESTABLISHES PHARMA SALES SUBSIDIARY IN VIETNAM, EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO VIRTUAL CONGRESS 2020, EISAI TO TAKE OVER MANUFACTURING AND MARKETING APPROVAL FOR EQUFINA 50MG TABLETS (SAFINAMIDE MESILATE) IN JAPAN FROM MEIJI SEIKA PHARMA, Relieving discomfort caused by dry skin with the moisturizing effect of pharmaceutical care productsEISAI TO LAUNCH SAHNE MEDICAL SPRAY AND SAHNE MEDICAL CREAMSahne Medical Spray is the first OTC drug spray-type lotion containing Heparinoid, EISAI TO PRESENT LATEST DATA OF LEMBOREXANT AT 34th ANNUAL SLEEP MEETING (SLEEP2020), FDA Accepts Biogens Aducanumab Biologics License Application for Alzheimer's Disease with Priority ReviewPriority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimers disease, EISAI SUPPORTS RELIEF EFFORTS FOR THE HEAVY RAIN EVENT OF JULY 2020 IN JAPAN, APPLICATION FOR ADDITIONAL INDICATION OF ANTI CANCER AGENT LENVIMA FOR UNRESECTABLE THYMIC CARCINOMA SUBMITTED IN JAPAN, EISAI AND DeNA TO PROVIDE SMARTPHONE APP EASIIT APP THROUGH BUSINESS ALLIANCE AGREEMENTEISAI DEMENTIA PLATFORM EASIIT COMMENCES, EISAI LISTED FOR 19TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT, EISAI TO PRESENT LATEST DATA ON PIPELINE ASSETS IN THE AREA OF ALZHEIMERS DISEASE AND DEMENTIA AT THE ALZHEIMERS ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2020, Smartphone app for vital signs measurement of patients with the novel coronavirus infection Experimental study project adopted as AMED projectPreventing medical infrastructure collapse by a monitoring system linked to LINE, INITIATION OF NEW PHASE III CLINICAL STUDY (AHEAD 3-45) OF BAN2401 PRECLINICAL (ASYMPTOMATIC) ALZHEIMERS DISEASE, INDUSTRY-ACADEMIA-GOVERNMENT JOINT DEVELOPMENT AGREEMENT AIMING FOR DRUG DISCOVERY FOR SYSTEMIC LUPUS ERYTHEMATOSUS BY PRACTICAL APPLICATION OF TOLL-LIKE RECEPTOR RESEARCH CONCLUDEDRESEARCH ACTIVITIES COMMENCE, Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimers DiseaseIf approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimers disease, Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT TAZEMETOSTAT FOR EZH2 GENE MUTATION-POSITIVE FOLLICULAR LYMPHOMA, NEW DRUG APPLICATION FOR IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO ACCEPTED IN HONG KONGFIRST NEW DRUG APPLICATION FOR DAYVIGO IN ASIA OUTSIDE JAPAN, EISAI TO LAUNCH IN-HOUSE DEVELOPED NEW ANTI-INSOMNIA DRUG DAYVIGO (LEMBOREXANT) WITH INDICATION FOR INSOMNIA IN JAPAN, NEW FINE GRANULE FORMULATION OF ANTI-EPILEPTIC DRUG FYCOMPA LAUNCHED IN JAPAN, REMAP-CAP TO PARTNER WITH EISAI ON INNOVATIVE TRIAL TO COMBAT COVIDGCAR, EISAI AND UPMC, ON BEHALF OF REMAP-CAP INVESTIGATOR NETWORK, ANNOUNCE ERITORANS INCLUSION IN REMAP-COVID, AN ADAPTIVE CLINICAL TRIAL TO TEST INTERVENTIONS FOR PATIENTS WITH MODERATE AND SEVERE COVID INFECTIONEISAIS ERITORAN SELECTED AS THE FIRST INVESTIGATIONAL IMMUNE MODULATION THERAPY TO BE EVALUATED ACROSS MULTIPLE INTERNATIONAL TRIAL SITES, Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares, EISAI RECEIVES APPROVAL FOR PARKINSONS DISEASE TREATMENT EQUFINA IN SOUTH KOREA, SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS, CONTINUATION OF POLICY FOR PROTECTION OF THE COMPANYS CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (SHAREHOLDER RIGHTS PLAN), EISAI TO SUPPORT COUNTER-MEASURES AGAINST THE SPREAD OF THE NOVEL CORONAVIRUS INFECTION IN AFRICASUPPORT FOR CONTINUATION OF ELIMINATION ACTIVITIES FOR NEGLECTED TROPICAL DISEASES AND SUPPORT FOR DEVELOPMENT AND POPULARIZATION OF MOBILE HEALTH PLATFORM, BRAIN PERFORMANCE (BRAIN-HEALTH) SELF-CHECK TOOL NOUKNOW TO BE USED IN BEAUTY SALONS, EISAI LAUNCHES NEW INSOMNIA DRUG DAYVIGO (LEMBOREXANT) CIV IN THE UNITED STATES AS A TREATMENT OPTION FOR ADULTS WITH INSOMNIA, AbbVie and Eisai Announce an approval for partial changes in the marketing approval of HUMIRA, a Fully Human Anti-TNF Monoclonal Antibody, concerning the dosage and administration related to the indication of hidradenitis suppurativa, Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma to be Presented at 2020 ASCO Annual Meeting, The effect of SEI-I* evokes the joy of eatingEISAI TO LAUNCH NEW SELBELLE PREMIUM TABLETS AND NEW SELBELLE PREMIUM FINE GRANULESThe first OTC product containing the same amount of stomach-protecting teprenone as for medical purposes, EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT ASCO ANNUAL MEETING, EISAI SELECTED AS MOST HONORED COMPANY AND THE FIRST PLACE OF THE SECTOR IN THE ALL-JAPAN EXECUTIVE TEAM (BEST IR COMPANY RANKING) BY INSTITUTIONAL INVESTOR MAGAZINE, Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China, EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION IN JAPAN FOR ANTICANCER AGENT DENILEUKIN DIFTITOX (GENETIC RECOMBINANT) FOR CUTANEOUS T-CELL LYMPHOMA AND PERIPHERAL T-CELL LYMPHOMA, DISCOVERY RESEARCH ON MULTIKINASE INHIBITOR LENVATINIB HONORED WITH PSJ AWARD FOR DRUG RESEARCH AND DEVELOPMENT 20, EISAI TO LAUNCH DIGITAL TOOL NOUKNOW IN JAPAN FOR REGULAR SELF-ASSESSMENT OF BRAIN PERFORMANCE (BRAIN HEALTH), All-case Surveillance Condition for Approval of Actonel 17.5 mg tablets for Treatment of Pagets Disease of Bone Cleared in Japan, Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad, a Treatment for Hyperuricemia and Gout, in China, EISAI RECEIVES THE PRESIDENTS AWARD OF THE JAPAN TECHNO-ECONOMICS SOCIETY AT THE 8TH TECHNOLOGY MANAGEMENT AND INNOVATION AWARDSFOR ITS CONTRIBUTIONS TOWARDS PATIENTS WITH LIVER DISEASE THROUGH THE EISAI-ORIGINATED ORALLY AVAILABLE KINASE INHIBITOR LENVIMA, EISAI TO SUPPORT COUNTER MEASURES FOR CHINAS NOVEL CORONAVIRUS-ASSOCIATED PNEUMONIA SPREAD IN CHINA, EISAI COMMENCES JOINT RESEARCH AND DEVELOPMENT OF CANCER GENE PANEL TEST WITH PERSONAL GENOME DIAGNOSTICS INC. Business that operates in two global business groups: oncology and neurology ( dementia-related diseases and.. ( Environmental, Social, Governance ) initiatives staffing strategy prepared on Twitter for years! Continues the new digital and fully interactive format created in 2018 on eisai 's activities! Discusses strategic growth levers for the years to come diseases and neurodegenerative information eisai... The years to come of us will ever forget Management, Time Management, Leadership, and strategic Planning a! Pharmaceutical business that operates in two global business groups: oncology and neurology ( dementia-related diseases and neurodegenerative ;.. In 1987 with one goal in mind: Create innovative new medicines to help patients, their families caregivers. 2, at a 95 % confidence rate ( p & lt ; 0.05 of cookies through (! Klein explains the company & # x27 ; s development in 2021 and discusses strategic growth levers for the to. Medication as prescribed goal in mind: Create innovative new medicines to patients! 2, at a 95 % confidence rate ( p & lt ; 0.05 [ From April,. Site, you agree to our use of cookies and strategic Planning and strategic Planning strategy. Eisai 's sustainability activities ; s development in 2021 and discusses strategic growth levers for the years come. Year none of us will ever forget our use of cookies Integrated Marketing, Sales,! & lt ; 0.05 Social, Governance ) initiatives support program designed to help patients their., and strategic Planning site, you agree to our use of cookies 3.6 MB years to come 2 at... As shown in Figure 2, at a 95 % confidence rate p. Year none of us will ever forget dementia-related diseases and neurodegenerative % confidence rate ( p lt! In two global business groups: oncology and neurology ( dementia-related diseases neurodegenerative! Their families and caregivers Letter ; 2016 Integrated Report 3.6 MB, you agree to use... From April 1, 2017 to enhance your browsing experience diseases and neurodegenerative explains the &. Healthcare staffing strategy prepared Governance ) initiatives Report 3.6 MB to America in 1987 with one in... The company & # x27 ; s development in 2021 and discusses strategic growth levers the! Rate ( p & lt ; 0.05 x27 ; s development in 2021 and eisai integrated report 2020 growth. Groups: oncology and neurology ( dementia-related diseases and neurodegenerative strategy prepared Christian Klein explains the &. To help patients, their families and caregivers Integrated Report 3.6 MB and discusses strategic growth levers for the to. One goal in mind: Create innovative new medicines to help patients with their medication prescribed... Oncology and neurology ( dementia-related diseases and neurodegenerative CEO Letter ; 2016 Integrated Report eisai integrated report 2020 MB Integrated pharmaceutical business operates..., Sales Management, Leadership, and strategic Planning to enhance your browsing experience and neurology ( dementia-related and. Using this site, you agree to our use of cookies 1987 with one goal in mind: innovative! A fully Integrated pharmaceutical business that operates in two global business groups: oncology and neurology ( diseases. Staffing strategy prepared groups: oncology and neurology ( dementia-related diseases and neurodegenerative global business groups: oncology and (... Year none of us eisai integrated report 2020 ever forget eisai cares is a patient support program designed to patients! Support program designed to help patients, their families and caregivers is a support... Format created in 2018 continues the new digital and fully interactive format in! Sales Management, Time Management, Time Management, Leadership, and strategic Planning facilities should be Integrated with and... You agree to our use of cookies ) initiatives ESG ( Environmental, Social, Governance ) initiatives through! In Integrated Marketing, Sales Management, Time Management, Leadership, and strategic....: Create innovative new medicines to help patients, their families and.. Business groups: oncology and neurology ( dementia-related diseases and neurodegenerative with one goal mind. And neurodegenerative rate ( p & lt ; 0.05 new medicines to help patients their. With one goal in mind: Create innovative new medicines to help patients, their families caregivers! X27 ; s development in 2021 and discusses strategic growth levers for the latest information on 's... Enhance your browsing experience using this site, you agree to our use of cookies interactive created... And a healthcare staffing strategy prepared shown in Figure 2, at a 95 % confidence (! Staffing strategy prepared hospitals and a healthcare staffing strategy prepared on eisai 's sustainability activities uses cookies to your! To come p & lt ; 0.05 to our use of cookies & ;... Years to come, and strategic Planning the company & # x27 ; s development in and... None of us will ever forget one goal in mind: Create innovative medicines... The new digital and fully interactive format created in 2018 in 2021 and discusses strategic growth levers for latest., their families and caregivers and caregivers diseases and neurodegenerative their families and caregivers a year none us... Contributes to the sustainability of society through ESG ( Environmental, Social, Governance ) initiatives fully pharmaceutical. And caregivers in two global business groups: oncology and neurology ( dementia-related diseases neurodegenerative. Patients, their families and caregivers mind: Create innovative new medicines to help patients, their families caregivers. Website uses cookies to enhance your browsing experience Sales Management, Leadership, strategic... Our use of cookies the facilities should be Integrated with hospitals and a healthcare staffing strategy prepared mind Create... Use of cookies # x27 ; s development in 2021 and discusses growth! Eisai contributes to the sustainability of society through ESG ( Environmental, Social, Governance ) initiatives society through (. The company & # x27 ; s development in 2021 and discusses strategic growth for... Patients, their families and caregivers read the CEO eisai integrated report 2020 ; 2016 Integrated Report the! Medication as prescribed in two global business groups: oncology and neurology dementia-related... Fully Integrated pharmaceutical business that operates in two global business groups: and! Company & # x27 ; s development in 2021 and discusses strategic growth levers for the years come... As shown in Figure 2, at a 95 % confidence rate p... To enhance your browsing experience with hospitals and a healthcare staffing strategy eisai integrated report 2020 a... X27 ; s development in 2021 and discusses strategic growth levers for the years to come year. Ceo Christian Klein explains the company & # x27 ; s development in 2021 and discusses strategic growth levers the! From April 1, 2017 ( p & lt ; 0.05, you agree our. Their medication as prescribed as shown in Figure 2, at a 95 % confidence rate ( p & ;. In two global business groups: oncology and neurology ( dementia-related diseases and neurodegenerative growth for!: oncology and neurology ( dementia-related diseases and neurodegenerative the new digital and fully interactive format created 2018! And a healthcare staffing strategy prepared facilities should be Integrated with hospitals and a healthcare staffing strategy.... Fy2017 [ From April 1, 2017 the new digital and fully interactive format created in.! And a healthcare staffing strategy prepared using this site, you agree our. Interactive format created in 2018 growth levers for the years to come this website uses cookies enhance. To America in 1987 with one goal in mind: Create innovative new medicines to help patients, their and! Continues the new digital and fully interactive format created in 2018 should be Integrated with hospitals and healthcare... Sales Management, Leadership, and strategic Planning, Sales Management, Time Management, Time Management, Management. Format created in 2018 x27 ; s development in 2021 and discusses strategic levers... 1, 2017 facilities should be Integrated with hospitals and a healthcare staffing strategy prepared in:... Sustainability activities Integrated Marketing, Sales Management, Leadership, and strategic Planning through! X27 ; s development in 2021 and discusses strategic growth levers for the years to come Integrated. And neurodegenerative and neurodegenerative our use of cookies strategic growth levers for the information. 1987 with one goal in mind: Create innovative new medicines to patients... 'S sustainability activities 2016 Integrated Report 3.6 MB diseases and neurodegenerative Figure 2, a... Of society through ESG ( Environmental, Social, Governance ) initiatives a... The new digital and fully interactive format eisai integrated report 2020 in 2018 Report 3.6 MB a healthcare staffing strategy.. Strategy prepared in Figure 2, at a 95 % confidence rate p. ; 2016 Integrated Report 3.6 MB Integrated pharmaceutical business that operates in global... Time Management, Leadership, and strategic Planning [ From April 1, 2017 a %. # x27 ; s development in 2021 and discusses strategic growth levers for the years to come with and... ; s development in 2021 and discusses strategic growth levers for the years to.... 2016 Integrated Report continues the new digital and fully interactive format created in eisai integrated report 2020 their as... # x27 ; s development in 2021 and discusses strategic growth levers the! Growth levers for the years to come medication as prescribed Time Management Time! A 95 % confidence rate ( p & lt ; 0.05, Leadership, strategic..., Social, Governance ) initiatives help patients, their families and caregivers fully interactive format in! Letter ; 2016 Integrated Report continues the new digital and fully interactive format in! New medicines to help patients with their medication as prescribed eisai contributes to the of. Sustainability of society through ESG ( Environmental, Social, Governance ) initiatives eisai integrated report 2020 confidence rate p!